COTI reports positive results from first phase of HIV integrase inhibitor discovery program

NewsGuard 100/100 Score
Critical Outcome Technologies Inc. (COTI) (TSX Venture: COT) today announced positive results from the first phase of its HIV integrase inhibitor discovery program.  These results provide novel intellectual property to the Company and further validation of the CHEMSAS® drug discovery technology.

The significance of these results is that the majority of currently marketed and developmental stage HIV Integrase inhibitors have a very similar way of interacting with and inhibiting the enzyme through a diketo acid type moiety.  COTI has used its proprietary technology, CHEMSAS®, to discover several novel small molecule scaffolds that have an entirely new binding mode and interaction with the active site of the viral enzyme.  

COTI has completed the synthesis and initial confirmatory in vitro testing of the first three novel scaffolds from this program.  All three scaffolds demonstrated good inhibitory activity in a biochemical HIV integrase assay at nanomolar concentrations.  On the basis of these results, COTI has filed composition of matter patents and intends to proceed with the next phase of this project that consists of optimizing a small series of potential lead candidates based on these scaffolds.

"These encouraging results provide further validation of our CHEMSAS® technology and its ability to rapidly identify innovative small molecules for difficult drug targets. The discovery of new HIV integrase inhibiting scaffolds having an entirely novel mode of interacting with the enzyme has been challenging for HIV researchers, which makes these early results quite gratifying," said Dr Wayne Danter, COTI's President and CSO. 

As previously announced, these novel scaffolds are part of a co-development program with a major pharmaceutical partner.  The co-development partner is now conducting and funding agreed upon in vitro experiments in their evaluation of the compounds.  Once these experiments have been completed and the results have been received by COTI, the co-development partner will have an exclusive time period to negotiate a licensing agreement with COTI for the compounds.


Critical Outcome Technologies Inc.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers develop precise drugs to target HIV's Nef protein